This site is intended for healthcare professionals
Cardiovascular Metabolism Learning Zone
Declaration of sponsorship Novartis Pharma AG

Hypertension

Declaration of sponsorship Novartis Pharma AG
Read time: 75 mins
Last updated:20th Jul 2021
Published:10th Jun 2021

Understand the influence of the renin-angiotensin system (RAS) on blood pressure and the different therapeutic options that target this pathway.

  • Watch the experts discuss the effectiveness of anti-hypertensive treatment classes
  • Explore the benefits of single pill combinations with Professor Düsing
  • Find relevant guideline updates, including advice in the context of COVID-19

The renin angiotensin system (RAS)

 

What is the RAS, how does it influence blood pressure, and what is its role in organ damage and disease?

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Why renin angiotensin aldosterone system (RAAS) blockers are a foundation antihypertensive therapy

 

With several drug classes available to treat hypertension, why are renin-angiotensin-aldosterone system (RAAS) blockers considered to be so important?

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Angiotensin receptor blockers (ARBs) versus angiotensin converting enzyme inhibitors (ACEIs): duration of action

 

What is the difference in duration of action between ARBs and ACEIs, and how can it be measured? Professor Williams provides clarity.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Calcium channel blockers (CCBs): mechanism of action

 

CCBs and Angiotensin Receptor Blockers (ARBs) both promote vasodilation. 

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Calcium channel blockers (CCBs) versus angiotensin receptor blockers (ARBs): efficacy

Key outcomes from the VALUE study are highlighted as we consider the relative benefits of CCBs and ARBs in relation to a range of cardiovascular sequalae.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Role of combination therapy in hypertension

 

Professor Rainer Düsing highlights the number of drugs required for hypertensive control across numerous intervention studies and considers a ‘rule of thirds’ in relation to combination therapy across a large patient population.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Hypertension update: use of ACEIs and ARBs in the context of COVID-19

video

Globally, what proportion of people are receiving treatment for hypertension and have their blood pressure under control? Guideline updates are designed to address the complexities of how to improve the ability of patients and clinicians to meet therapeutic targets.

The COVID-19 pandemic has required scientists, clinicians and patients to review data which is rapidly updating and evolving. Understanding if COVID-19 may affect the treatment of hypertension offers benefit in relation to decisions about effective drug therapy, and the data presented here are based on recommendations and statements from global medical and scientific societies.

  • Find key information related to drug therapy for hypertension in the context of COVID-19
  • Gain clarity regarding situations in which angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) might require discontinuation, based on clinical picture and not directed by COVID-19 status
  • Ensure that the rationale for initiating treatment for hypertension is well-understood
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: